EMJ GOLD
banner
emjgold.bsky.social
EMJ GOLD
@emjgold.bsky.social
270 followers 2.1K following 92 posts
The latest pharma news, views and analysis. Sign up to our mailing list to receive insights direct to your inbox: https://emjreviews.com/mailing-list/
Posts Media Videos Starter Packs
Pinned
Pharma headlines only tell part of the story.

Our brand-new monthly roundup goes further, sharing the context and analysis behind the biggest news. In this edition, learn about AI’s hidden risks and the off-label trends behind the GLP-1 boom.

Read now: www.emjreviews.com/emj-gold/new...
"It’s not just about removing inflammation, but for people to accept, like and feel comfortable in their skin again"

This #WorldMentalHealthDay, Dr Volker Koscielny, Almirall, explores the need to better address the mental health burden of skin conditions hubs.ly/Q03N3VZB0
🧠 What if mind-controlled devices didn’t require invasive surgery?

A new study by Precision Neuroscience shows a surface-based brain-computer interface can capture high-resolution signals without opening the skull.

Read more: www.emjreviews.com/emj-gold/new...
Potential breakthrough in brain-computer interface research
New research from Precision Neuroscience shows its brain-computer interface can record high-resolution signals without invasive surgery.
www.emjreviews.com
UK healthcare stocks are powering the FTSE 100 to record highs - with AstraZeneca leading the charge and policy shifts in the US opening new doors for pharma. Could this be the turning point for the sector?

Read the full story here: www.emjreviews.com/emj-gold/new...
FTSE 100 hits new high as UK pharma stocks surge
UK pharma and healthcare stocks drive FTSE 100 to a record high, led by AstraZeneca, as trade policy shifts boost investor confidence.
www.emjreviews.com
Pharma headlines only tell part of the story.

Our brand-new monthly roundup goes further, sharing the context and analysis behind the biggest news. In this edition, learn about AI’s hidden risks and the off-label trends behind the GLP-1 boom.

Read now: www.emjreviews.com/emj-gold/new...
What could the tariffs mean for your company?

Announcing the plan on his Truth Social platform, President Trump said drugmakers could avoid the 100% duties if they have broken ground on a domestic plant on US soil.

Learn more: www.emjreviews.com/emj-gold/new...

#pharmatariffs
US pharma tariffs: Trump threatens 100% on imports
Donald Trump has threatened sweeping new tariffs on the pharma sector unless manufacturers commit to producing in the US.
www.emjreviews.com
Social media: What does pharma need to know in 2025?

Discover key trends, challenges and opportunities, with some surprises in store, in our latest article.

Check it out now: www.emjreviews.com/emj-gold/art...
Can Pfizer become an obesity market leader?

With its $4.9bn acquisition of Metsera, the pharma giant is signalling its desire to conquer one of the industry’s fastest-growing areas.

Read the story: www.emjreviews.com/emj-gold/new...
Pfizer enters obesity race with $4.9bn Metsera deal
Pfizer is claiming a space in the global obesity market as it announces plans to acquire weight loss drug developer Metsera for $4.9bn.
www.emjreviews.com
Roche is set to acquire US-based 89bio in a deal worth up to $3.5B.

The acquisition brings a late-stage therapy for MASH - an area with no approved treatments - into Roche’s pipeline, strengthening its focus on cardiovascular, renal and metabolic diseases: www.emjreviews.com/emj-gold/new...
Roche acquires US biotech 89bio for $3.5bn
Roche acquires 89bio in a $3.5B deal, adding a late-stage MASH therapy and expanding its focus on cardiovascular and metabolic diseases.
www.emjreviews.com
Can ChatGPT really be trusted for medical advice?

A new study suggests not yet. When researchers tested the AI on common patient questions about COPD, they found its answers were consistent, but often incomplete.

Read more: www.emjreviews.com/emj-gold/new...
New study reveals risks of patients using ChatGPT
Patients are increasingly turning to ChatGPT for medical advice, but new research warns it isn’t yet accurate enough to be relied on alone.
www.emjreviews.com
Germany was once the “pharmacy of the world”.

Today, its strengths in research, investment and patient access give it a chance to reclaim that crown. But with hurdles in financing, regulation and digital adoption, the question is: can it lead the pack once more?
www.emjreviews.com/emj-gold/art...
The UK is slipping in the global pharma race. An ABPI & PwC report shows R&D growth, investment, and clinical trial activity are all in decline. Urgent action is needed to stay competitive.

Read more 👉 www.emjreviews.com/emj-gold/new...
ABPI report highlights decline in UK pharma investment
UK falls in global pharma R&D and clinical trials competitiveness, ABPI report warns, urging action to unlock investment and patient access.
www.emjreviews.com
Could one therapy treat 100+ diseases?

According to Phesi, GLP-1s, once for diabetes and weight loss, are now in trials across cancers, MASLD, PCOS and more. But what challenges lie ahead?

Discover now: www.emjreviews.com/emj-gold/new...
GLP-1 therapies in trials for 100+ diseases, Phesi finds
Phesi analysis shows GLP-1 therapies moving beyond diabetes and obesity into 100+ diseases, from cancer to cardiovascular conditions.
www.emjreviews.com
"Great leadership is about navigating paradoxes. You’ve got to think big and long-term, while delivering flawlessly day to day."

In our latest interview, hear from Fabrice Chouraqui, CEO, Pharming, as he shares his top leadership lessons and more.

🔗 www.emjreviews.com/emj-gold/art...
5 minutes with Fabrice Chouraqui, CEO, Pharming
Fabrice Chouraqu, CEO, Pharming, explores his journey into the pharma industry, a typical day for a CEO and his key leadership lessons.
hubs.la
Can smaller biotechs finally compete on drug discovery?

Eli Lilly and Company’s TuneLab will share AI models to support new innovation, joining a wave of other pharma companies opening up their platforms.

Read the story: hubs.ly/Q03HzMxl0
Lilly's TuneLab to share AI models with small biotechs
Lilly has launched TuneLab, giving biotech companies access to AI-powered drug discovery models based on over £1bn in research investment.
hubs.ly
Celebrating the future of science! 🌟

Thermo Fisher Scientific has recognised 300 of America’s brightest middle school innovators in the 2025 Junior Innovators Challenges, tackling real-world challenges from AI to disease detection and sustainability.

Read more: www.emjreviews.com/emj-gold/new...
Rising STEM stars take home Thermo Fisher Award
A group of 300 middle schoolers are named in the 2025 Thermo Fisher Junior Innovators Challenge for STEM projects in AI to climate change.
hubs.la
🚨 Big investment in UK health tech

Newcastle University has secured £22m from NIHR to expand its horizon scanning work – with the aim of identifying the next medicines, diagnostics and digital tools set to transform care.

Read more: www.emjreviews.com/emj-gold/new...
Newcastle University wins £22m UK's NIHR health tech award
The National Institute for Health and Care Research (NIHR) is funding Newcastle Univeristy's work in emerging diagnostics, devices and more.
hubs.la
Pharma is taking psychedelics seriously. AbbVie has just made a billion-dollar bet on a next-generation therapy for depression. See why they invested in this candidate from Gilgamesh Pharmaceuticals👉 www.emjreviews.com/emj-gold/new...
A new roundtable is live – and this one’s for the pharma marketers.

We spoke to leaders from across the industry to uncover what’s cutting it with today’s HCPs. Unsurprisingly, there are shared challenges, but also plenty of potential solutions.

Read now: hubs.la/Q03DNkV40